Sesen Bio, Inc.
245 First Street, Suite 1800
Cambridge, MA 02142
May 13, 2021
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Deanna Virginio
Re: | Sesen Bio, Inc. |
Registration Statement on Form S-3 | |
Filed May 10, 2021 | |
File No. 333-255943 |
Request for Acceleration of Effective Date
Dear Ms. Virginio:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Sesen Bio, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Daylight Time, on May 14, 2021, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours, | ||
Sesen Bio, Inc. | ||
/s/ Thomas R. Cannell, D.V.M. | ||
By: | Thomas R. Cannell, D.V.M. | |
Title: | President and Chief Executive Officer |